Akademik Veri Yönetim Sistemi
Journal of Drug Delivery Science and Technology, cilt.116, 2026 (SCI-Expanded, Scopus)
Dermal drug delivery has recently become a prominent topic for the topical treatment of skin-specific diseases such as actinic keratosis. In skin-related diseases, increased efficacy and reduced side effects can be achieved by increasing the amount of drug accumulated in the target tissue and reducing systemic exposure. In this study, elastic vesicular system formulations were developed to increase the penetration and accumulation of diclofenac sodium in the skin for the treatment of actinic keratosis. The vesicle systems containing diclofenac sodium, Lipoid S100, cholesterol, Transcutol CG, oleic acid, and hyaluronic acid were produced by the film hydration method and characterized in terms of vesicle size, polydispersity index, zeta potential, encapsulation efficiency, viscosity, morphology, and elasticity. Cytotoxicity and ex vivo skin permeation/skin accumulation studies were also performed on the optimum formulations. In ex vivo studies, the selected optimum vesicle system formulation (V4, which contained 20 mg of diclofenac sodium, 125 mg of Lipoid S100, 62.5 mg of cholesterol, and 30 mg of Transcutol CG), which provided the highest drug accumulation in the rat skin, was used in stability and in vivo studies. It was found that V4 was stable for 3 months at 5 °C. In the in vivo studies, a xylene-induced ear edema model was utilized. The efficacy of V4 was evaluated, and it was found to be superior to the commercial product. It was concluded that vesicle systems developed can be used in the effective treatment of actinic keratosis.